ASKA Pharmaceutical Holdings (4886) · InitiativeFirst stated
Joint Research With Teijin Pharma Limited in Gynecological Diseases
First written in FY2026. . Latest entry: FY2026.
2entries
1years
1from disclosures
How it moved
Same theme, other companies
Expansion of Collaborative Research and Development Alliances with Domestic and Overseas Pharmaceutical CompaniesA theme 11 companies write about · 0 as a headwind · 14 as a tailwind
The whole theme swung hardest in 2022: 1 of 6 companies on the "Worse" side.
0 other companies' latest entry also says "First stated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2026First statedAnnual report
「In February 2026, we entered into a joint research agreement with Teijin Pharma Limited to create novel small-molecule drug candidates for gynecological diseases.」
婦人科疾患領域の新規低分子医薬品候補化合物の創出を目的として、帝人ファーマ株式会社と2026年2月に共同研究契約を締結した。 - 2026-05-11First statedEarnings
「In February 2026, we entered into a joint research agreement with Teijin Pharma Limited to create novel small-molecule drug candidates for gynecological diseases.」
The company newly reported a joint research agreement with Teijin Pharma for novel small-molecule drug candidates in gynecological diseases.